Agios Pharmaceuticals Inc (AGIO)

Agios slides after discontinuing development of tebapivat in myelodysplastic syndromes (AGIO)May 29, 2026 10:26 AM
IH Market News Shares drop following disappointing mid-stage trial outcome Agios Pharmaceuticals (NASDAQ:AGIO) came under pressure on Friday, with shares falling 13% after the company announced it would halt development of tebapivat for lower-risk myelodysplastic syndromes (LR-MDS). The decision follows results from a Phase 2b study that failed to achieve the internal criteria required to support further development of the oral pyruvate kinase activator in this indication, representing a setback for the biotechnology group. Trial failed to demonstrate sufficient clinical benefit The open-label, multicentre study evaluated tebapivat over a 24-week treatment period in 65 patients with lower-risk myelodysplastic syndromes and anaemia. Participants received once-daily doses of 10mg, 15mg or 20mg, with the primary endpoint focused on transfusion independence. The company defined success as patients remaining free from blood transfusions for at least eight consecutive weeks during the treatment period. Although the trial produced signs of biological activity, the treatment did not generate meaningful clinical benefit in enough patients to justify advancing the programme into later-stage development. Safety profile remained favourable Despite the disappointing efficacy outcome, Agios reported that tebapivat was generally well tolerated across all dose groups. The company said no new safety concerns emerged during the study, and the overall safety profile remained consistent with previous observations. Management highlights complexity of the disease Commenting on the results, Agios executives noted the challenges involved in developing effective therapies for lower-risk myelodysplastic syndromes. “The results from the Phase 2b trial underscore the biological complexity of lower-risk myelodysplastic syndromes and the challenges of identifying patients most likely to benefit,” said Sarah Gheuens, Chief Medical Officer and Head of R&D at Agios. The outcome reinforces the difficulty of treating LR-MDS, a group of bone marrow disorders that can cause chronic anaemia and often require ongoing blood transfusions. Focus shifts to sickle cell disease programme While development in LR-MDS has been discontinued, Agios remains committed to exploring tebapivat’s potential in other indications. The company said it continues to see promise for the drug as a treatment for sickle cell disease and is progressing clinical development in that area. Agios expects to report topline results from an ongoing Phase 2 study evaluating tebapivat in sickle cell disease during the second half of 2026. Investors will now be looking to that programme as the next major catalyst for the asset following the setback in myelodysplastic syndromes. Agios Pharmaceuticals stock price Original: Agios slides after discontinuing development of tebapivat in myelodysplastic syndromes (AGIO)

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with ThalassaemiaMay 22, 2026 10:18 AM
Business Wire Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemolysis, which together place a significant burden on patients, including a substantial impact on quality of life and persistent fatigue,” commented Raffaella Origa M.D., PhD., Professor of Paediatrics at University of Cagliari, Italy and President of the Italian Society of Thalassaemia and Haemoglobinopathies (SITE). “The approval of PYRUKYND in the EU represents an important step forward, introducing a new oral treatment option regardless of genotype or transfusion burden, with the potential to address key aspects of the disease, including reducing transfusion burden and improving patient outcomes.” The EC’s decision follows the positive opinion issued by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) and is based on results from the global, randomised, double-blind, placebo-controlled ENERGIZE and ENERGIZE-T Phase 3 trials. The approval of PYRUKYND for adults with thalassaemia marks its second indication in the EU, following its 2022 approval for adults with PK deficiency. “The treatment of thalassaemia continues to place a profound burden on patients and healthcare systems,” said Antonis Kattamis M.D., Professor at the National & Kapodistrian University of Athens, Greece, and an investigator in the PYRUKYND thalassaemia Phase 3 clinical program. “An oral therapy such as PYRUKYND has the potential to transform the care of both transfusion-dependent and non-transfusion-dependent patients, and we welcome being able to provide this option in our clinical practice.” In June 2025, Avanzanite entered into an exclusive agreement with Agios to commercialise and distribute PYRUKYND across the European Economic Area, the United Kingdom, and Switzerland. Avanzanite will continue to work closely with Agios, local health authorities and patient communities to secure access for PYRUKYND across the EU. “Today’s approval of Agios’ first-in-class PK activator in the EU is great news for adults living with thalassaemia and we are proud and privileged to partner with Agios to distribute and commercialise this medicine in the region,” said Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Our role now is to collaborate with local authorities, drive a successful launch, and enable broad access to PYRUKYND in this indication, helping to ensure no thalassaemia patient is left behind, across the EU.” This milestone represents the fourth rare disease launch that Avanzanite has led, further demonstrating the strength of its pan-European commercial platform. With a ‘Champions League’ team of more than 100 rare disease professionals conducting operations spanning 32 European countries, the company is well-positioned to partner with biotech innovators to deliver transformative therapies to patients across Europe. About Thalassaemia Thalassaemia is a rare, inherited blood disease that affects the production of haemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. The disease is categorised into two main types: alpha-thalassaemia and beta-thalassaemia, depending on which globin chain of the haemoglobin is affected. By disrupting haemoglobin production, thalassaemia reduces the number of circulating red blood cells and shortens their lifespan, which leads to anaemia, fatigue, and serious complications. Some individuals with thalassaemia require regular transfusions (classified as transfusion-dependent thalassaemia), while others only need them intermittently (classified as non-transfusion-dependent thalassaemia). All patients with thalassaemia experience a significant disease burden, including comorbidities, reduced quality of life and shortened life expectancy. About ENERGIZE and ENERGIZE-T ENERGIZE (NCT04770753) and ENERGIZE-T (NCT04770779) are global, double-blind, placebo-controlled Phase 3 trials evaluating the efficacy and safety of mitapivat in adults with alpha- or beta-thalassaemia. The ENERGIZE trial randomised 194 non-transfusion-dependent alpha- or beta-thalassaemia patients 2:1 to receive either mitapivat 100 mg twice daily or placebo. The primary endpoint was haemoglobin response, defined as an increase of ≥1.0 g/dL in average haemoglobin concentration from Week 12 through Week 24 compared with baseline. Key secondary endpoints included changes from baseline in average fatigue scores and in average haemoglobin concentration from Week 12 to Week 24. The trial also assessed safety and tolerability. The ENERGIZE-T trial randomised 258 transfusion-dependent alpha- or beta-thalassaemia patients 2:1 to receive either mitapivat 100 mg twice daily or placebo. The primary endpoint was transfusion reduction response, defined as a ≥50% reduction in transfused red blood cell (RBC) units with a reduction of ≥2 units of RBCs transfused in any consecutive 12-week period through Week 48 compared with baseline. Several transfusion reduction measures were included as key secondary endpoints, and achievement of transfusion independence was a secondary endpoint. The trial also assessed safety and tolerability. For each trial, patients who completed the double-blind period had the option to transition into a corresponding open-label extension period, during which all patients receive mitapivat. About Avanzanite Bioscience Avanzanite is redefining launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the Netherlands, the company partners with biotech innovators to unlock the full commercial value of orphan medicines through a fully integrated platform spanning 32 countries. With our deep expertise in market access, we navigate Europe’s complex landscape like master chess players – ensuring no patient is left behind while delivering measurable impact and growth opportunities for alliance partners. For more information, visit www.avanzanite.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260522186975/en/ Avanzanite Bioscience B.V.
Phone: +31 20 301 21 13
Email: media@avanzanite.com
Website: www.avanzanite.com Original: Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

Agios shares jump as FDA discussions advance mitapivat approval pathwayMarch 31, 2026 11:06 AM
IH Market News
Agios Pharmaceuticals (NASDAQ:AGIO) shares climbed about 12% on Tuesday after the company reported progress toward a potential accelerated U.S. approval for its drug candidate mitapivat in treating sickle cell disease following a pre-supplemental New Drug Application meeting with the U.S. Food and Drug Administration.During the discussions, the FDA advised Agios to submit a proposal outlining a confirmatory clinical trial that could support an accelerated approval pathway for mitapivat, an oral pyruvate kinase activator. Accelerated approval allows treatments addressing serious conditions with unmet medical needs to reach patients sooner, provided that additional studies later confirm the drug’s clinical benefit.Agios said it has already submitted its proposal for the required confirmatory trial to the FDA for review. The design includes a primary endpoint different from those used in the RISE UP clinical program, drawing on data analyses from the program as well as regulatory discussions.The company plans to file a supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease in the coming months. It is also continuing discussions with the FDA to align on the details of the confirmatory trial needed to support the submission.Based on its current plans, Agios said the proposed study is not expected to alter its previously issued operating expense outlook, which remains projected to be roughly flat compared with 2025.The recent regulatory meeting focused on data from the RISE UP clinical program, which includes both Phase 2 and Phase 3 trials evaluating mitapivat in patients with sickle cell disease.Agios Pharmaceuticals stock price

Original: Agios shares jump as FDA discussions advance mitapivat approval pathway

they all leave and the stock keeps declining...
Imagine FOUSE leaving.... stock would be up?

aged well
FOUSE and Schenkein too busy delaying trials and engagin the analyst to pump their stock.

management selling a sheet ton of shares vs delivering and helping patients.
its still a good product

AGIO new 52 week high

AGIO new 52 week high

Do you have any estimates?

Lots of posts.
There is a short position that will have to be covered, so a short squeeze is probably in progress.
Stay safe.

News: $AGIO Agios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for Investors

There's an old adage in biotech -- raise capital when you can, not when you have to -- that  Agios Pharmaceuticals (NASDAQ: AGIO) seems to have taken to heart. The biotech ended the third quarter with over $540 million in the bank, which it estimated would last through at least the end o...

Got this from AGIO - Agios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for Investors

News: $AGIO Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

– Plasma SAM Biomarker Indicates Robust Target Engagement at Well Tolerated Doses; AG-270 Maximum Tolerated Dose Determined to be 200 mg Once Daily – – Combination Arms of Phase 1 Study Evaluating AG-270 in Combination with Taxanes in Non-Small Cell Lung Cancer an...

In case you are interested AGIO - Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

$AGIO Bullish after-hours 15% move on positive 8-K filing

Shares have made a very positive move afterhours on good volume after the release of its 8-K Inc announcing that the global phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib) in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 mutation met its primary endpoint. Tomorrow will be a very positive day so be ready, it could move very fast.

AGIOS UP BIG AFTER HOURS

Agios just another pump and dump??

Be careful investors, do your research, take a closer look. Agios is a company involved in developing biologic drugs.....the CSO of Agios is a chemist..... the person holding such a position is supposed to be a biologist, someone with a background in biology, not small molecule drugs.


The truth is the CSO has no experience in his background to make him suitable for such a position.....

VistaTrades issed a BUY signal for AGIO on 4.17.17

AGIO $64.00, sweetness....

AGIO $55.60 pre market...weeeeeeeeeeeeeeeeeeeee

AGIO $54 and more to come.....yea baby.....

AGIO $52.30

AGIO $50 coming soon......monster in the making here!

AGIO, nice bottom bounce play here.... +$2.55

Could easily hit $50 by tomorrow.

R2G, great support $46+ AGIO

low vol, let's hit $50+ today.....AGIO

AGIO $48.90 p/m

AGIO, back to $47.00 she's got legs.......glad I held the (3 hour dip) lol

AGIO $47.75 getting there

grabbed some @ $46.50 1K, c'mon $50 AGIO

AGIO $47.39

AGIO $47.18

AGIO $46.93

AGIO $46 !!!!!

AGIO $42.98

Agios Pharmaceuticals, Inc. (the “Company”) today announced that its collaboration partner Celgene Corporation (“Celgene”) expects to submit a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for enasidenib (AG-221), a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-2 (“IDH2”), in relapsed and/or refractory acute myeloid leukemia (“AML”). The NDA will be based on data from the ongoing phase 1/2 study of AG-221 in patients with advanced hematologic malignancies with an IDH2 mutation. The NDA submission is expected to occur by year-end 2016. Celgene will be discussing the planned enasidenib NDA submission at the Citi 11th Annual Biotech Conference in Boston in a webcast event on Wednesday, September 7, 2016 at 12:00 pm ET.

AGIO $41.70 ca$h money

AGIO $40.60 wow

AGIO $39.97 going. $40+

AGIO $38.40

In at 36.6

$AGIO DD Notes ~ http://www.ddnotesmaker.com/AGIO

bullish
quick trade
long term trend fine

$AGIO recent news/filings

## source: finance.yahoo.com

Fri, 26 Dec 2014 18:21:01 GMT ~ Nasdaq stocks posting largest percentage increases

[AP] - A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.: OvaScience Inc. rose 34.9 percent to $47.16. Tetraphase Pharmaceuticals Inc. rose 14.9 percent to $38.14. Dicerna Pharma rose 14.8 percent ...

read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220237991--finance.html
*********************************************************

Tue, 23 Dec 2014 19:35:25 GMT ~ Biotech Stocks Sell Off, ETFs Fall Over 5%


read full: http://finance.yahoo.com/news/biotech-stocks-sell-off-etfs-193525958.html
*********************************************************

Tue, 23 Dec 2014 18:44:00 GMT ~ 5 Stocks With Major Insider Buying: Agios Pharmaceuticals and More


read full: http://www.thestreet.com/story/12994553/1/5-stocks-with-major-insider-buying-agios-pharmaceuticals-and-more.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Tue, 23 Dec 2014 16:17:01 GMT ~ Biotech Bull Markets and Billion-Dollar Valuations


read full: http://finance.yahoo.com/tumblr/blog-biotech-bull-markets-and-billion-dollar-valuations-161706408.html
*********************************************************

Sat, 20 Dec 2014 14:10:29 GMT ~ Despite Huge Rally, High-Profile Insiders Still Buying Stocks


read full: http://247wallst.com/investing/2014/12/20/despite-huge-rally-high-profile-insiders-still-buying-stocks/
*********************************************************


$AGIO charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$AGIO company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/AGIO/company-info
Ticker: $AGIO
OTC Market Place: Not Available
CIK code: not found
Company name: Agios Pharmaceuticals, Inc.
Incorporated In:

Business Description:


$AGIO share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$AGIO extra dd links

Company name: Agios Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AGIO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AGIO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AGIO+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/news - http://finance.yahoo.com/q/h?s=AGIO+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AGIO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AGIO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AGIO
DTCC (dtcc.com): http://search2.dtcc.com/?q=Agios+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Agios+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Agios+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AGIO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AGIO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AGIO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AGIO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AGIO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AGIO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AGIO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AGIO+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AGIO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AGIO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AGIO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AGIO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AGIO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AGIO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AGIO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AGIO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AGIO



$AGIO DD Notes ~ http://www.ddnotesmaker.com/AGIO

AGIO M

AGIO D

$AGIO MLV Reiterates Buy On Agios Pharmaceuticals Following AG-221 Clinical Data Release http://www.smarteranalyst.com/2014/12/10/mlv-reiterates-buy-on-agios-pharmaceuticals-following-ag-221-clinical-data-release/

$AGIO Agios Pharmaceuticals: We Expect Multiple Catalysts To Support The Stock, Says MLV http://www.smarteranalyst.com/2014/12/04/agios-pharmaceuticals-we-expect-multiple-catalysts-to-support-the-stock-says-mlv/

$AGIO Canaccord Sets Expectations On Agios Ahead Of ASH Annual Meeting http://www.smarteranalyst.com/2014/12/03/canaccord-sets-expectations-on-agios-ahead-of-ash-annual-meeting/

$AGIO DD Notes ~ http://www.ddnotesmaker.com/AGIO

bullish

$AGIO recent news/filings

## source: finance.yahoo.com

Wed, 26 Nov 2014 23:02:57 GMT ~ Nasdaq stocks posting largest percentage increases


read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220237991--finance.html
*********************************************************

Wed, 26 Nov 2014 21:06:51 GMT ~ AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ


read full: http://biz.yahoo.com/e/141126/agio8-k.html
*********************************************************

Thu, 20 Nov 2014 20:33:25 GMT ~ Agios (AGIO) Shares Up on Positive AG-120 Study Data


read full: http://finance.yahoo.com/news/agios-agio-shares-positive-ag-203325054.html
*********************************************************

Thu, 20 Nov 2014 14:48:00 GMT ~ Agios Pharmaceuticals (AGIO) Showing Signs Of Perilous Reversal Today


read full: http://www.thestreet.com/story/12961804/1/agios-pharmaceuticals-agio-showing-signs-of-perilous-reversal-today.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Thu, 20 Nov 2014 06:50:38 GMT ~ Agios Pharmaceuticals (AGIO) in Focus: Stock Rises 14.5%


read full: http://finance.yahoo.com/news/agios-pharmaceuticals-agio-focus-stock-065038882.html
*********************************************************


$AGIO charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$AGIO company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/AGIO/company-info
Ticker: $AGIO
OTC Market Place: Not Available
CIK code: not found
Company name: Agios Pharmaceuticals, Inc.
Incorporated In:

Business Description:


$AGIO share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$AGIO extra dd links

Company name: Agios Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AGIO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AGIO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AGIO+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/news - http://finance.yahoo.com/q/h?s=AGIO+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AGIO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AGIO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AGIO
DTCC (dtcc.com): http://search2.dtcc.com/?q=Agios+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Agios+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Agios+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AGIO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AGIO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AGIO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AGIO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AGIO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AGIO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AGIO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AGIO+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AGIO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AGIO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AGIO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AGIO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AGIO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AGIO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AGIO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AGIO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AGIO



$AGIO DD Notes ~ http://www.ddnotesmaker.com/AGIO

Week over week at time highs . where it stop one know not.

expansion . From 8K "rentable square footage of the New Premises from approximately 74,500 square feet to approximately 113,220 square feet."

good gain . when split ?